GlaxoSmithKline PLC ADR (GSK)
GlaxoSmithKline PLC ADR (GSK) carries a ŷRobot AI score of 65 out of 100. The model's fair value estimate is $52.11, 6.3% above the last close of $49.02. The chart signal reads Hold.
| Metric | GSK |
|---|---|
| AI score | 65 / 100 |
| Chart signal | Hold |
| Fair value estimate | $52.11 |
| Upside to fair value | 6.3% |
| Previous close | $49.02 |
| P/E | 15.47 |
| Price / sales | 2.12 |
| Market cap | $92.70B |
| EPS | 3.05 |
| Revenue growth | -2.2% |
| 1-year price change | -0.0% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, UnitedHealth Group Incorporated, Merck & Company Inc, Novartis AG ADR.
Questions about GSK
Is GSK overvalued or undervalued right now?
As of Oct 15, 2026, ŷRobot's fair-value model estimates GlaxoSmithKline PLC ADR (GSK) at $52.11 against a last close of $49.02, implying 6.3% upside to the model's estimate.
Is GSK's chart signal bullish or bearish?
The chart-signal model classifies GSK as Neutral as of Oct 15, 2026, with a signal score of 0.14 on a -1 to 1 scale.
What is GSK's ŷRobot AI score?
GSK scores 65 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 15, 2026.
Is GSK stock expensive on P/E and P/S?
GSK trades at 15.5 times earnings and 2.1 times sales as of Oct 15, 2026.
What does GSK's seasonal forecast show?
ŷRobot's seasonal forecast curve for GSK reads -0.4% at 30 days, +0.5% at 90 days, and -0.0% at one year as of Oct 15, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is GSK growing?
GlaxoSmithKline PLC ADR's revenue growth is -2.2% and free-cash-flow growth is +2.2% on the latest reported figures.
GSK chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.